Investigational Drug Information for Otamixaban
✉ Email this page to a colleague
What is the drug development status for Otamixaban?
Otamixaban is an investigational drug.
There have been 5 clinical trials for Otamixaban.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2010.
The most common disease conditions in clinical trials are Acute Coronary Syndrome, Renal Insufficiency, and Myocardial Infarction. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Summary for Otamixaban
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 699 |
| WIPO Patent Applications | 374 |
| Japanese Patent Applications | 162 |
| Clinical Trial Progress | Phase 3 (2010-04-01) |
| Vendors | 40 |
Recent Clinical Trials for Otamixaban
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment | Sanofi | Phase 1 |
| Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy | Sanofi | Phase 3 |
| Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment | Sanofi | Phase 1 |
Clinical Trial Summary for Otamixaban
Top disease conditions for Otamixaban
Top clinical trial sponsors for Otamixaban
US Patents for Otamixaban
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
